
News
Latest press releases – plus an archive of press releases, thus recording milestones and key facts in Sunstone’s history.
MinervaX raises upsized EUR 47.4M Series B to advance its novel Group B Streptococcus vaccine through mid-stage clinical trials
MinervaX, a privately held Danish biotechnology company developing a novel vaccine against Group B Streptococcus (GBS), announced today that it has raised an upsized EUR 47.4 million Series B financing. The round included new investors Sanofi Ventures, Wellington...
The FDA grants IO Biotech breakthrough therapy designation for IO102 and IO103 in combination with anti-PD-1 in unresectable/metastatic melanoma
IO Biotech today announced that the FDA has granted breakthrough therapy designation for a combination of the potential therapy IO102 and IO103 with anti-PD-1 mAb for patients with unresectable/ metastatic melanoma. Press inquiries should be adressed to:...
Kim Stratton, CEO, resigns from Orphazyme
Orphazyme A/S (ORPHA.CO) (“Orphazyme”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces that Kim Stratton has decided to resign from Orphazyme following a...
Sunstone announces new investment in neuropsychiatric company Synendos Therapeutics
Copenhagen, 12 November 2020 – Sunstone Life Science Ventures today announces it has invested in a new portfolio company, Synendos Therapeutics AG (“Synendos”), a biopharmaceutical company dedicated to developing novel therapeutics for the treatment of a wide range of...
Sunstone portfolio company Galecto in successful IPO on Nasdaq Global Market in the US.
Sunstone today announced its portfolio company Galecto, a clinical stage biotech firm focusing on novel therapeutics for fibrosis and inflammatory-related lung diseases, successfully has launched an initial public offering (IPO) on Nasdaq Global Market in the U.S....
Sunstone welcomes Novo Holdings A/S as new LP in Sunstone Life Science Ventures Fund IV
Sunstone today announced that Novo Holdings A/S has joined as Limited Partner (LP) in Sunstone’s latest fund; Sunstone Life Science Ventures Fund IV (“Sunstone IV”) Sunstone has been collaborating with Novo Seeds and Novo Ventures, both a part of Novo Holdings, for...